The Insulin‑Like Growth Factor Axis: Molecular Insights for Metabolic‑Related Basic Research
Physiological Composition and Core Signalling Outputs of the IGF System
The insulin‑like growth factor system forms a complex regulatory network composed of IGF ligands, cell‑surface IGF receptors and more than six distinct insulin‑like growth factor‑binding proteins (IGFBPs). IGF‑1 and IGF‑2 serve as primary growth‑promoting ligands within this physiological signalling network for mammalian model systems. These ligands act through autocrine, paracrine and endocrine routes to bind corresponding membrane‑localized receptor molecules.
Receptor‑ligand engagement triggers downstream activation of PI3‑kinase / protein‑kinase B and mitogen‑activated protein‑kinase signalling cascades inside target cells. Such signalling events drive measurable cellular outputs including proliferation, differentiation and cell survival across embryonic development, post‑natal growth and tissue‑repair experimental models. IGFBPs function not merely as circulating carrier proteins to modulate ligand half‑life and bioavailability.
These binding proteins can regulate cell‑cycle progression, apoptotic events and metabolic phenotypes via IGF‑dependent or IGF‑independent molecular mechanisms. Functional crosstalk exists between IGF‑associated cascades and insulin‑driven signalling pathways at multiple molecular levels. Both systems jointly govern energy homeostasis and tissue‑growth phenotypes, attracting sustained attention from metabolism‑oriented basic‑research communities.
Molecular Profile Alterations of IGF Components Under Adiposity‑Related Experimental Conditions
Research datasets document measurable differences in IGF‑system readouts between sample groups representing distinct adiposity status in human‑relevant laboratory studies. At circulating protein levels, elevated IGFBP‑4 concentrations appear alongside reduced IGFBP‑1, IGFBP‑2 and IGFBP‑6 quantities within obese sample cohorts. Declined IGFBP‑1 and IGFBP‑2 may indirectly amplify local IGF biological activity given their ligand‑inhibitory properties.
Elevated IGFBP‑4 observed in these sample sets follows complex regulatory patterns and may participate in adipose‑tissue remodelling processes. Transcript‑level data from adipose tissue specimens further reveal up‑regulated IGFBP‑7 gene expression alongside down‑regulated IGF‑2, IGFBP‑1 and IGFBP‑6 transcription. These transcript‑level shifts indicate adiposity‑associated transcriptional reprogramming targeting multiple IGF‑axis components.
Multiple correlative relationships connect IGF‑system molecules to metabolic readouts linked to energy balance and hormone regulation. IGFBP‑6 concentrations show positive correlation with appetite‑ and energy‑balance‑modulating factors such as apelin, cholecystokinin, GLP‑1 and leptin‑receptor molecules. IGFBP‑1 and IGFBP‑2 display negative correlation against fasting‑insulin measurements, suggesting potential roles supporting insulin‑sensitivity maintenance.
Body‑mass‑index and blood‑pressure‑related parameters show positive correlation with IGFBP‑3 and negative correlation with IGFBP‑1 plus IGFBP‑2 within analysed datasets. Circulating leptin levels exhibit inverse correlation with IGF‑2, IGFBP‑1 and IGFBP‑2, reflecting endocrine crosstalk between adipocyte‑secreted mediators and the IGF regulatory network. These inter‑correlated molecular patterns embed the IGF axis within broader whole‑body metabolic hormone circuits.
Proposed Mechanistic Hypotheses Linking IGF‑Axis Dysregulation to Adipose‑Tissue Biology
Several mechanistic frameworks interpret how IGF‑system disturbances may drive adiposity‑related phenotypes in laboratory‑based research projects. First, IGF‑1 supports pre‑adipocyte differentiation and adipogenesis processes within cell‑culture experimental systems. Down‑regulated IGFBP‑1 and IGFBP‑2 can enhance local IGF bioavailability and may facilitate excessive adipocyte hyperplasia and hypertrophy in adipose‑tissue samples.
Second, overlapping downstream signalling nodes connect IGF‑receptor cascades with insulin signal transduction pathways. Reduced IGFBP‑1 levels may worsen insulin‑resistance phenotypes and create self‑reinforcing molecular feedback loops in metabolic model systems. Third, selected IGF‑binding proteins exert pro‑inflammatory or anti‑inflammatory effects independent of IGF ligands, modifying inflammatory microenvironments inside adipose tissues.
Fourth, IGF ligands and certain IGFBPs can cross biological barrier structures such as the blood‑brain barrier in experimental animal models. These molecules may reach hypothalamic brain regions and exert direct modulatory influence over feeding behaviours and central energy‑metabolism regulatory circuits. Many mechanistic details remain incompletely characterized and require further cell‑based and animal‑model experimental validation.
Recombinant IGF‑I Research Reagents from ANT BIO PTE. LTD. for Metabolism‑Focused Laboratory Investigation
ANT BIO PTE. LTD. supplies recombinant insulin‑like growth factor‑I protein reagents covering multiple species origins for metabolism and growth‑biology basic‑research workflows. The mouse‑derived IGF‑I Protein (catalog UA040099) is expressed in E.coli and validated through MCF‑7 cell‑proliferation functional assays for consistent bioactivity. Multi‑step chromatographic purification achieves purity above 98 % measured via SDS‑PAGE and RP‑HPLC analytical techniques.
Endotoxin levels stay below 1.0 EU/μg for this reagent, supporting reliable performance in cell‑culture work and animal‑model intervention experiments. Strict quality‑control workflows limit intra‑batch and inter‑batch variability to improve experimental reproducibility for long‑term serial laboratory projects. Researchers deploy these IGF‑I protein reagents across diverse experimental scenarios.
Major application directions include growth‑and‑metabolism mechanistic studies in mouse experimental systems, intervention treatment for ageing‑related or muscle‑atrophy animal models, in‑vitro drug‑candidate screening targeting IGF‑1R signalling, and supplementation for primary‑cell or cell‑line cultivation setups. Full technical documentation including mass‑spectrometry reports and functional validation datasets is accessible for end‑user reference.
Related Product Portfolio
| Catalog No. | Product Name | Host | Expression System | Conjugation | Lead Time | Available Sizes |
|---|---|---|---|---|---|---|
| UA040515 | LR3‑IGF‑I Protein, Human/Porcine/Bovine | Human | E.coli | Unconjugated | In stock | 10 μg, 50 μg, 100 μg, 500 μg, 1 mg |
| UA100025 | IGF‑I Protein, Human | Human | E.coli | Unconjugated | In stock | 10 μg, 50 μg, 100 μg, 500 μg, 1 mg |
| UA040099 | IGF‑I Protein, Mouse | Mouse | E.coli | Unconjugated | In stock | 10 μg, 50 μg, 100 μg, 500 μg, 1 mg |
| UA040109 | IGF‑I Protein, Rat | Rat | E.coli | Unconjugated | In stock | 10 μg, 50 μg, 100 μg, 500 μg, 1 mg |
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.
